GlassScriptPhysician profile
Aaron S Gold
NPI 1548412711
$8,629.57
in general payments reported to CMS, 2019-2025
21 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,174 · 2020: $84.68 · 2021: $396 · 2022: $222 · 2023: $521 · 2024: $1,914 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,648 · Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,648.00 |
| Food and Beverage | $1,104.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $4,540.20 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $1,821.60 | 2024 | Eylea |
| Aerie Pharmaceuticals, INC. | $363.59 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $246.86 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $167.13 | 2025 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $151.92 | 2019 | |
| Shire North American Group INC | $147.83 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $147.80 | 2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $143.88 | 2021 | |
| Sight Sciences, INC. | $123.57 | 2022 | |
| Genzyme Corporation | $121.99 | 2019 | |
| Astellas Pharma US INC | $121.83 | 2025 | Izervay |
| Maculogix, INC. | $113.03 | 2019 | |
| Biotissue Holdings INC. | $106.82 | 2023 | |
| Coopervision INC. | $98.85 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $92.51 | 2024 | Total30 |
| Allergan, INC. | $32.15 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $28.93 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $26.08 | 2021 | |
| Oyster Point Pharma, INC. | $19.33 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.